Sugi Predict

Sugi Predict / Compounds / SCHEMBL1570136

SCHEMBL1570136

SCHEMBL1570136

NCCc1cc(Cl)ccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 7/20 0.56
▸ HTR2A P28223 1/20 0.50
▸ TRPM8 Q7Z2W7 1/20 0.50
▸ PNMT P11086 1/20 0.48
▸ TP53 P04637 2/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MAOB P27338 2/20 0.42
▸ IDO1 P14902 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30496773 1.00 TAAR1 (0.56) TAAR1HTR2ATRPM8PNMTTP53
SCHEMBL29787088 0.82 IDO1 (0.56) TAAR1HTR2ATRPM8TSHRMAOB
SCHEMBL473578 0.82 IDO1 (0.56) TAAR1HTR2ATRPM8TSHRMAOB
SCHEMBL1570195 0.82 TAAR1 (0.52) TAAR1HTR2ATRPM8MAOBIDO1
SCHEMBL42557 0.81 PNMT (0.52) PNMTTP53TSHRIDO1
Hydrochloric Acid SCHEMBL3591333 0.80 IDO1 (0.57) TAAR1HTR2ATRPM8MAOBIDO1
SCHEMBL5108087 0.80 CYP3A4 (0.50) TAAR1HTR2ATRPM8TP53TSHR
Hydrochloric Acid SCHEMBL28650595 0.80 IDO1 (0.57) TAAR1HTR2ATRPM8MAOBIDO1
Hydrochloric Acid SCHEMBL3734261 0.79 PNMT (0.50) HTR2APNMTTP53TSHRIDO1
SCHEMBL9183333 0.79 TP53 (0.46) TP53TSHRIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110964705-A Novel application of (R) -omega-transaminase mutant 浙江科技学院 2020-04-07 — — CN claimed
CN-117510429-A Compound containing methyl isoxazole structure, and preparation method and application thereof 中国农业大学 2024-02-06 — — CN disclosed
CN-111848494-B Guanidine compounds and uses thereof 伊谬诺米特医疗有限公司 2023-08-01 — — CN disclosed
EP-3131877-B1 BIGUANIDE COMPOUNDS IMMUNOMET THERAPEUTICS INC (US) 2023-07-19 — — EP disclosed
US-11572374-B2 N-cyano-7-azanorbornane derivatives and uses thereof AMGEN INC. (US) 2023-02-07 — — US disclosed
US-11572374-B2 N-cyano-7-azanorbornane derivatives and uses thereof AMGEN INC. (US) 2023-02-07 — — US disclosed
US-20220363694-A1 N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF AMGEN INC. (US) 2022-11-17 — — US disclosed
US-11465989-B2 Guanidine compounds and use thereof ImmunoMet Therapeutics, Inc. (US) 2022-10-11 — — US disclosed
CN-111848494-A Guanidine compounds and uses thereof 伊谬诺米特医疗有限公司 2020-10-30 — — CN disclosed
CN-110964705-A Novel application of (R) -omega-transaminase mutant 浙江科技学院 2020-04-07 — — CN disclosed
US-8716498-B2 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA, INC. (US) 2014-05-06 — — US disclosed
US-20140005418-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2014-01-02 — — US disclosed
US-8569522-B2 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC. (US) 2013-10-29 — — US disclosed
US-20110105463-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2011-05-05 — — US disclosed
EP-2307397-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES Array Biopharma, Inc. (US) 2011-04-13 — — EP disclosed
EP-2185503-A1 MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-05-19 — — EP disclosed
WO-2009158426-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2009-12-30 — — WO disclosed
WO-2009016087-A1 MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 — — WO disclosed
US-20090036422-A1 MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 — — US disclosed
WO-2004024728-A2 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-03-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11465989-B2 Guanidine compounds and use thereof PC, TFAM, PCK2 TAAR1 4576/4885HTR2A 3793/4885TRPM8 3926/4885
US-20110105463-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES GPR52, CD22, CD4 TAAR1 337/4885HTR2A 258/4885TRPM8 2655/4885
US-11572374-B2 N-cyano-7-azanorbornane derivatives and uses thereof CYP3A7, CYP51A1, NT5C3B TAAR1 2240/4885HTR2A 4645/4885TRPM8 4208/4885
US-20140005418-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES UGT1A6, UGT2B7, UGT1A7 TAAR1 3058/4885HTR2A 3246/4885TRPM8 4858/4885
US-20090036422-A1 MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, MTNR1A TAAR1 80/4885HTR2A 107/4885TRPM8 385/4885
US-20220363694-A1 N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF CYP3A7, CYP51A1, NT5C3B TAAR1 2240/4885HTR2A 4645/4885TRPM8 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.